

Regimen Reference Order – CNS - bevacizumab

ARIA: CNS – [bevacizumab]

Planned Course: Every 28 days until disease progression or unacceptable toxicity

Indication for Use: Glioblastoma Multiforme

CVAD: At Provider's Discretion

Proceed with treatment if:

Day 1 ONLY

- *Platelets equal to or greater than $75 \times 10^9/L$*
- *Proceed regardless of ANC value*
 - ❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – CNS - bevacizumab

Establish primary solution 500 mL of: normal saline (bevacizumab incompatible with D5W)

Drug	Dose	CCMB Administration Guideline
bevacizumab (brand name specific)	10 mg/kg	IV in normal saline 100 mL over 20 minutes on Days 1 and 15 <i>*Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order</i>

All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See CNS DSG – Dose Banding document for more information

Flush after each medication:

- 50 mL over 6 minutes (500 mL/hr)

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

All Cycles

Day 1 only

- CBC, biochemistry, liver functions, urine protein and blood pressure as per Physician Orders
 - Urinalysis for protein: Where urinalysis is not possible, use dipstick. If lab urinalysis for protein is greater than or equal to 1g/L or dipstick proteinuria shows 2+ or 3+, notify prescriber

Days 1 and 15

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O2 saturation) at baseline and as clinically indicated
- No observation period is required
- Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

DISCHARGE INSTRUCTIONS

- N/A

ADDITIONAL INFORMATION

- bevacizumab causes increased risk of hypertension, post-operative bleeding, wound healing complications and thromboembolic events
- bevacizumab is available from more than one manufacturer and uses several different brand names. Brand name will be indicated in brackets after bevacizumab. **Ensure prescription label matches the brand name on prescribed order**